Barclays raised the firm’s price target on Tenet Healthcare (THC) to $229 from $208 and keeps an Overweight rating on the shares. The firm incorporated preliminary estimates of newly approved state directed payments in Texas and updated price targets across the healthcare facilities and managed care group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $225 from $205 at BofA
- Tenet Healthcare’s Strategic Positioning and Growth Potential Justify Buy Rating
- 3 “Strong Buy” Value Stocks to Buy Now, 8/6/2025, According to Analysts
- Tenet Healthcare downgraded to Peer Perform from Outperform at Wolfe Research
- Tenet Healthcare price target lowered to $167 from $195 at Baird